Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in return for no ...
A startup tackling the 'dumb problems' at the intersection of AI and bio, accuracy of AI scribes, and more.
UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of ...
Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.
The next DSM and the algorithm, an unexpected discovery on alpha-gal syndrome, and more health news from Morning Rounds ...
The new DSM, expected in 2030, should address the digital environments of eating disorders patients, experts write.
UniQure submitted applications to the FDA and the UK’s MHRA, seeking the marketing approval of AMT-130, its treatment for ...
The whole of my field has been flattened into a single lazy question: Did the health care system fail her?” writes Jennifer ...
Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for ...
With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the ...
The federal spending bill has an important provision for researchers, and Trump announced more MFN deals with pharma firms.
An NIH proposal to cap the number of research grants investigators can receive has drawn a mixed reception, the agency says.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results